Most Recent
In COVID-19 vaccination cases, judge quashes subpoena ‘stunt’ for info behind Berejiklian TV remarks
A judge has set aside a subpoena that allegedly sought to “embarrass the New South Wales government”, in lawsuits contesting compulsory COVID-19 vaccination orders made by state health minister Brad Hazzard.
An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug was wrongly granted.
Avant Insurance has lost a bid to pause an order that it pay $371,000 in the legal costs of a surgeon facing a class action by breast implant patients of defunct clinic the Cosmetic Institute while the insurer's appeal is pending.
Hundreds of women who suffered “chaos and devastation” at the hands of former surgeon Emil Gayed will be entitled to compensation after class action law firm Slater & Gordon negotiated with the state government to secure a redress scheme.
Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.
Botox maker Allergan has successfully challenged a Federal Court judgment dismissing its trade mark lawsuit against an Australian company selling topical creams as an alternative to Botox injections.
Avant Insurance has launched an appeal of a Federal Court judgment ordering it to cover the defence costs of a surgeon facing a class action by breast implant patients of defunct clinic the Cosmetic Institute.
Tens of thousands of hospital patients were put at risk when Medtronic unlawfully supplied a bone grafting kit to hospitals that was not registered on the Australian Register of Therapeutic Goods, according to new regulatory proceedings.
The Commissioner of Patents has appealed a landmark judgment that found artificial intelligence can be named an inventor on a patent application.
Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.